Johnson & Johnson (JNJ) reported Q2 2025 financial results before market open.
The company posted revenue of $23.74 billion, surpassing estimates of $22.85 billion and marking a 5.7% increase from $22.45 billion a year ago.
Adjusted earnings were $2.77 per share, beating estimates of $2.68 but down 1.8% compared to $2.82 in the prior year. For FY 2025, earnings outlook is revised to $10.80 to $10.90, above the estimate of $10.62.
Revenue outlook for FY 2025 is also raised to $93.20 billion to $93.60 billion, exceeding the estimate of $91.40 billion.
